Article
Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
European journal of gastroenterology & hepatology - 1 Mar 2021
Hinrichsen Holger, Stoehr Albrecht, Cornberg Markus, Klinker Hartwig, Heyne Renate, John Christine, Simon Karl-Georg, Guenther Veronika, Martin Karen, Witte Vanessa, Zeuzem Stefan
Abstract excerpt
BACKGROUND: For treatment of genotype 1a (GT1a) infection with elbasvir/grazoprevir, the German guidelines recommend a differentiated approach depending on baseline viral load (BVL). For low BVL ≤800 000 IU/mL, treatment with 12 weeks elbasvir/grazoprevir should be considered, whereas for high BVL >800 000 IU/mL, this regimen is only recommended in nonstructural protein 5A (NS5A) resistance-associated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.